New Evidence for Transmitter Role of VIP in The Airways: Impaired Relaxation by a Catalytic Antibody-Reference-Cited by-同舟云学术

New Evidence for Transmitter Role of VIP in The Airways: Impaired Relaxation by a Catalytic Antibody

Published:2002-05 Issue:2 Volume:15 Page:121-127
ISSN:1094-5539
Container-title:Pulmonary Pharmacology & Therapeutics
language:en
Short-container-title:Pulmonary Pharmacology & Therapeutics

Author:

Berisha H.I.,Bratut M.,Bangale Yogesh,Colasurdo G.,Paul S.,Said Sami I.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Biochemistry, medical,Pulmonary and Respiratory Medicine

Reference32 articles.

1. Vasoactive intestinal peptide: a possible transmitter of nonadrenergic relaxation of guinea pig airways;Matsuzaki;Science,1980

2. Vasoactive intestinal peptide as a possible transmitter of nonadrenergic, noncholinergic relaxation of pulmonary artery;Kubota;Trans Assoc Am Physicians,1985

3. Autonomic innervation of pulmonary artery: evidence for a nonadrenergic noncholinergic inhibitory system;Kubota;Exp Lung Res,1988

4. Nitric oxide: physiology, pathophysiology, and pharmacology;Moncada;Pharmacol Rev,1991

5. Nitric oxide is the endogenous transmitter of bronchodilator nerves in humans;Belvisi;Eur J Pharmacol,1992

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial;Trials;2022-09-20

2. Aviptadil: Class Effect of a Synthetic Vasoactive Intestinal Peptide as a Treatment Option in Patients with COVID-19 with Severe Respiratory Failure;EMJ Microbiology & Infectious Diseases;2022-01-10

3. Aviptadil- Class Effect of a Synthetic Vasoactive Intestinal Peptide as a Treatment Option in COVID-19 Patients with Severe Respiratory Failure;Indian Journal of Respiratory Care;2022-01-04

4. Neural control of the lower airways: Role in cough and airway inflammatory disease;Respiratory Neurobiology - Physiology and Clinical Disorders, Part I;2022

5. Proatherogenic Sialidases and Desialylated Lipoproteins: 35 Years of Research and Current State from Bench to Bedside;Biomedicines;2021-05-25